Omega 3 fatty acid supplementation improves myocardial function, oxidative stress in Rett syndrome
Tuesday, February 25, 2014. An article that appeared on January 12, 2014 in the journal Mediators of Inflammation reports a benefit for supplementation with omega 3 polyunsaturated fatty acids (PUFAs) in Rett syndrome, a neurodevelopmental disorder that is associated with a 300-fold increased risk of sudden cardiac death in comparison with that of the general population.
The study included 66 female Rett syndrome patients of an average age of 12 years. Half of the participants received twice daily supplements of fish oil containing the omega 3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for one year, while the remainder received no supplementation. Echocardiography evaluated myocardial function before and after the treatment period, and blood samples collected at the beginning of the study and at six and twelve months were analyzed for plasma free isoprostanes (markers of oxidative stress) and other factors.
Omega-3-supplemented subjects experienced a reduction in oxidative stress markers after twelve months, whereas the control group had no significant changes. Myocardial dysfunction and clinical severity also significantly improved among those who received omega 3 while remaining relatively unchanged in unsupplemented patients. The researchers also observed significant improvements in attention, breathing abnormalities, muscle tone, movement, autonomic dysfunction, and growth in supplemented subjects.
"Our current working hypothesis on the beneficial effects of omega 3 PUFAs in Rett syndrome is that the increased isoprostane levels in Rett syndrome are not simply the effect of the peroxidation of the PUFAs precursors following the attack by radical oxygen species (ROS), but rather the effect of a potential dysregulation of the molecular targets of omega 3 PUFAs," write authors Silvia Maffei of University Hospital AOUS in Siena, Italy and her colleagues. "Contrary to expectations, the assumed fatty acids are not further oxidized, while the actual endogenous isoprostanes production is reduced (the "fatty acid paradox") together with amelioration of the clinical disease severity."
"Taken as a whole, these findings suggest that oxidative stress may play a key role in the systolic performance of the Rett syndrome myocardium and that it can be at least partially rescued by omega 3 PUFAs dietary supplementation," they write.
An article published online on March 24, 2010 in the Journal of Nutrition revealed the finding of Dutch researchers that increased fish and omega-3 fatty acid consumption is associated with a lower risk of fatal coronary heart disease (CHD) in a population with low fish intake.
Researchers at Wageningen University analyzed data from 21,342 participants in The Monitoring Project on Risk Factors for Chronic Diseases (MORGEN) study of men and women aged 20 to 65, in which information on diet, lifestyle and cardiovascular risk factors was collected from 1993 to 1997. Questionnaire responses provided information on type and frequency of fish consumed, which was analyzed for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content. The subjects were followed until January, 2007 during which fatal coronary heart disease and nonfatal heart attacks were documented.
Over the follow-up period, 647 deaths occurred. Eight-two deaths were caused by coronary heart disease, which included 64 heart attacks. Nonfatal heart attacks were documented in 252 subjects. Participants whose intake of EPA and DHA was among the top 25 percent of subjects at a median of 234 milligrams per day had a 49 percent lower risk of fatal coronary heart disease and a 62 percent lower risk of fatal heart attack compared with those whose intake was lowest at 40 milligrams. Those whose fish intake was among the top 25 percent experienced similar benefits. No association was found between fish or EPA and DHA intake and nonfatal heart attack.
The authors hypothesize that the different associations observed for fatal and nonfatal heart attack are due to EPA and DHA's protective effect against fatal cardiac arrhythmias.
"In a population with low levels of fish consumption, higher intakes of EPA+DHA and fish may protect against fatal CHD in a dose-responsive manner," they conclude.
†This supplement should be taken in conjunction with a healthy diet and regular exercise program. Results may vary.
Integra-Lean® Irvingia is protected by U.S. Patent No. 7,537,790. Other patents pending. IGOB-131® proprietary extract is a registered trademark of Gateway Health Alliances, Inc. Meratrim® is a proprietary ingredient derived from natural plant extracts exclusively distributed by InterHealth N.I.
D-glucarate is found in grapefruit, apples, oranges, broccoli, and Brussels sprouts. D-glucarate supports the body's cleansing system — a detoxification mechanism called glucuronidation. The human body uses glucuronidation to make a large variety of substances more water-soluble, and, in this way, allow for their subsequent elimination from the body through urine or feces (via bile from the liver).